Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on October 24, 2019, to announce its third-quarter 2019 financial results. The report primarily directs investors to a press release (Exhibit 99.1) for detailed financial information. This press release contains both GAAP and non-GAAP financial measures, with management believing the non-GAAP figures offer a useful supplementary view for investors, as they are used internally for operational and financial planning. Investors are advised to review the reconciliation tables provided in the press release for a clear understanding of the differences between GAAP and non-GAAP reporting. The core of this filing is the dissemination of Gilead's quarterly performance. While the 8-K itself is brief, the accompanying press release is expected to contain critical data points such as revenue, earnings per share, and potentially insights into key drug performance and future outlook. Investors should examine the full press release to assess the company's financial health and operational progress during the period ended September 30, 2019.
Key Highlights
- 1Gilead Sciences announced its third-quarter 2019 financial results on October 24, 2019, via an 8-K filing.
- 2The 8-K filing refers investors to Exhibit 99.1, a press release, for detailed financial results.
- 3The press release includes both GAAP (Generally Accepted Accounting Principles) and non-GAAP financial information.
- 4Management considers non-GAAP financial measures useful for investors, citing internal use for operational and financial planning.
- 5A reconciliation between GAAP and non-GAAP financial information is provided within the press release.
- 6The information in this 8-K and its exhibit are furnished and not considered 'filed' for certain regulatory purposes.
- 7The filing includes the cover page interactive data file in the specified exhibit format.